Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The agreement leverages complementary resources to develop Innovent's early-stage oncology pipeline with greater speed and global impact, expanding Innovent's reach via co-commercialization in the U.S. and Europe and laying the foundation for a global oncology platform.

  60% confidence

• The collaboration combines Innovent's discovery and early clinical development with Pfizer's global R&D and commercialization capabilities to accelerate breakthroughs that can redefine standards of care for cancer patients.

  60% confidence

Data points we hold from this source